fluorouracil has been researched along with Animal Mammary Carcinoma in 21 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adjuvant chemotherapy is used for human breast cancer patients, even after curative surgery of primary tumor, to prevent tumor recurrence primarily as a form of metastasis." | 5.48 | Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| "Most breast cancers originate in the epithelial cells lining the breast ducts." | 2.76 | Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. ( Brown, RJ; Gabrielson, E; Huso, DL; Jacobs, LK; Jeter, S; Khouri, NF; Kominsky, SL; Lange, JR; Mori, T; Powers, P; Rudek, MA; Stearns, V; Sukumar, S; Tarpinian, K; Tsangaris, TN; Yoshida, T; Zhang, Z, 2011) |
| "Adjuvant chemotherapy is used for human breast cancer patients, even after curative surgery of primary tumor, to prevent tumor recurrence primarily as a form of metastasis." | 1.48 | Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| "CRF has been detected in breast cancer tissues; however, the biological effects reported in the literature are sparse and variable." | 1.40 | Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice. ( Reed, RK; Stuhr, LE; Wei, ET, 2014) |
| " In this study, we investigated the efficiency of transgene delivery and the cytotoxic effects of alphaviral vector in combination with 5-fluorouracil (5-FU) in a mouse mammary tumor model (4 T1)." | 1.40 | High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model. ( Kozlovska, T; Plotniece, A; Skrastina, D; Spaks, A; Vasilevska, J; Zajakina, A; Zhulenkovs, D, 2014) |
| "Capecitabine is a novel fluoropyrimidine carbamate, which has a broader spectrum of antitumor activity than other fluoropyrimidines, such as 5-FU, DFUR, or UFT; it has proved effective over a wide dose range." | 1.35 | Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. ( Kang, X; Wang, J; Yang, B; Yang, F; Zhang, Q, 2008) |
| "DISC-hGMCSF was able to infect all breast carcinoma cell lines and the majority of primary breast carcinoma cultures with high efficiency, although culture-to-culture variability in infectability was noted in the latter." | 1.32 | Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma. ( Curry, J; Hoogstraten, C; Leigh Shaw, M; Loudon, PT; Martin, G; McLean, CS; Osanto, S; Verdegaal, E, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (19.05) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abu-Serie, MM | 1 |
| Abdelfattah, EZA | 1 |
| Farboudi, A | 1 |
| Nouri, A | 1 |
| Shirinzad, S | 1 |
| Sojoudi, P | 1 |
| Davaran, S | 1 |
| Akrami, M | 1 |
| Irani, M | 1 |
| Baboli, M | 1 |
| Winters, KV | 1 |
| Freed, M | 1 |
| Zhang, J | 1 |
| Kim, SG | 1 |
| Zhou, B | 1 |
| Zhang, D | 1 |
| Pei, SM | 1 |
| Zhang, H | 1 |
| Du, HC | 1 |
| Jin, YP | 1 |
| Lin, DG | 1 |
| Sasaki, S | 1 |
| Baba, T | 1 |
| Muranaka, H | 1 |
| Tanabe, Y | 1 |
| Takahashi, C | 1 |
| Matsugo, S | 1 |
| Mukaida, N | 1 |
| Stuhr, LE | 1 |
| Wei, ET | 1 |
| Reed, RK | 1 |
| Zajakina, A | 1 |
| Vasilevska, J | 1 |
| Zhulenkovs, D | 1 |
| Skrastina, D | 1 |
| Spaks, A | 1 |
| Plotniece, A | 1 |
| Kozlovska, T | 1 |
| Schem, C | 1 |
| Tower, RJ | 1 |
| Kneissl, P | 1 |
| Rambow, AC | 1 |
| Campbell, GM | 1 |
| Desel, C | 1 |
| Damm, T | 1 |
| Heilmann, T | 1 |
| Fuchs, S | 1 |
| Zuhayra, M | 1 |
| Trauzold, A | 1 |
| Glüer, CC | 1 |
| Schott, S | 1 |
| Tiwari, S | 1 |
| Zhang, Q | 1 |
| Kang, X | 1 |
| Yang, B | 1 |
| Wang, J | 1 |
| Yang, F | 1 |
| Stearns, V | 1 |
| Mori, T | 1 |
| Jacobs, LK | 1 |
| Khouri, NF | 1 |
| Gabrielson, E | 1 |
| Yoshida, T | 1 |
| Kominsky, SL | 1 |
| Huso, DL | 1 |
| Jeter, S | 1 |
| Powers, P | 1 |
| Tarpinian, K | 1 |
| Brown, RJ | 1 |
| Lange, JR | 1 |
| Rudek, MA | 1 |
| Zhang, Z | 1 |
| Tsangaris, TN | 1 |
| Sukumar, S | 1 |
| Loudon, PT | 1 |
| McLean, CS | 1 |
| Martin, G | 1 |
| Curry, J | 1 |
| Leigh Shaw, M | 1 |
| Hoogstraten, C | 1 |
| Verdegaal, E | 1 |
| Osanto, S | 1 |
| CRANSTON, EM | 1 |
| STROUD, AN | 1 |
| MCDONALD, GO | 1 |
| SVOBODA, BR | 1 |
| BRUES, AM | 1 |
| MCALISTER, WH | 1 |
| DIPAOLO, JA | 1 |
| Kossoy, G | 1 |
| Ben-Hur, H | 1 |
| Avinoach, I | 1 |
| Alhayany, A | 1 |
| Shneider, DF | 1 |
| Zusman, I | 1 |
| Sasaki, T | 1 |
| Fujimori, M | 1 |
| Hamaji, Y | 1 |
| Hama, Y | 1 |
| Ito, K | 1 |
| Amano, J | 1 |
| Taniguchi, S | 1 |
| Stolfi, RL | 2 |
| Colofiore, JR | 1 |
| Nord, LD | 1 |
| Martin, DS | 3 |
| Koutcher, JA | 1 |
| Alfieri, AA | 1 |
| Thaler, H | 1 |
| Matei, C | 1 |
| Karayannopoulou, M | 1 |
| Kaldrymidou, E | 1 |
| Constantinidis, TC | 1 |
| Dessiris, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma[NCT01717066] | 480 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer[NCT00290732] | Phase 1 | 20 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maximum tolerated dose (MTD) of administering pegylated liposomal doxorubicin (PLD) into one duct of women with breast cancer awaiting mastectomy. MTD reflects highest dose of drug that did not cause Dose Limiting Toxicity (DLT) in more than 30% of patients. (NCT00290732)
Timeframe: Until up to 30 days after PLD administration
| Intervention | milligrams (Number) |
|---|---|
| Intraductal Arm | 10 |
Due to the limited number of samples and detectable levels, the maximum concentration of doxorubicin in blood (plasma) across all the participants in each group is reported. (NCT00290732)
Timeframe: Baseline, 4 hrs, day2/24 hrs, day 8, day of surgery/biopsy
| Intervention | nM (Number) | |
|---|---|---|
| Doxorubicin, max | Doxorubicinol, max | |
| Intraductal Arm- 0 mg PLD | 0 | 0 |
| Intraductal Arm- 10 mg PLD | 902.0 | 36.9 |
| Intraductal Arm- 2 mg PLD | 28.5 | 0 |
| Intraductal Arm- 5 mg PLD | 18.3 | 0 |
| Intravenous Arm | 79300 | 8090 |
Due to the limited number of samples and detectable levels, the maximum concentration of doxorubicin in tissue across all the participants in each group is reported. (NCT00290732)
Timeframe: Day of surgery/biopsy
| Intervention | nmol/g (Number) | |
|---|---|---|
| Doxorubicin, max | Doxorubicinol, max | |
| Intraductal Arm- 0 mg PLD | 0 | 0 |
| Intraductal Arm- 10 mg PLD | 10.82 | 5.26 |
| Intraductal Arm- 2 mg PLD | 0 | 0 |
| Intraductal Arm- 5 mg PLD | 1.73 | 0.09 |
| Intravenous Arm | 0.21 | 0 |
1 trial available for fluorouracil and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Preclinical and clinical evaluation of intraductally administered agents in early breast cancer.
Topics: Adult; Animals; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Doxorubicin; Drug Administrati | 2011 |
20 other studies available for fluorouracil and Animal Mammary Carcinoma
| Article | Year |
|---|---|
A comparative study of smart nanoformulations of diethyldithiocarbamate with Cu
Topics: Aldehyde Dehydrogenase; Animals; Ditiocarb; Female; Fetal Hypoxia; Fluorouracil; Humans; Liver Neopl | 2023 |
Synthesis of magnetic gold coated poly (ε-caprolactonediol) based polyurethane/poly(N-isopropylacrylamide)-grafted-chitosan core-shell nanofibers for controlled release of paclitaxel and 5-FU.
Topics: Acrylic Resins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chitosan; | 2020 |
Evaluation of metronomic chemotherapy response using diffusion and dynamic contrast-enhanced MRI.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Case-Control Studies; Contrast | 2020 |
Establishment of 5-Fluorouracil-resistant canine mammary tumor cell line.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Dog Diseases; Dogs; Drug Resistance, Neo | 2017 |
Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL2; Cyclophosphamide; D | 2018 |
Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice.
Topics: Animals; Apoptosis; Breast Neoplasms; Corticotropin-Releasing Hormone; Female; Fluorouracil; Humans; | 2014 |
High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.
Topics: Alphavirus; Animals; Cell Line; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; | 2014 |
Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Topics: Alendronate; Animals; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Caspases; Cell | 2017 |
Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; D | 2008 |
Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Separation; Centr | 2003 |
Ineffectiveness of five compounds on spontaneous mammary tumors of mice.
Topics: Animals; Chlorprothixene; Fluorouracil; Hydrocarbons; Mammary Neoplasms, Animal; Mice; Naphthoquinon | 1963 |
UTILIZATION OF DNA AND RNA PRECURSORS AS INDICATORS OF DRUG EFFECT ON CANCER CELLS. ANL-6723.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dactinomycin; DNA; DNA, Neoplasm; Fluorour | 1963 |
COMPARISON OF THE EFFECTS OF CHEMOTHERAPY AND LOCAL IRRADIATION ON THE VASCULARITY OF A TRANSPLANTED MOUSE MAMMARY ADENOCARCINOMA AND A PLEOMORPHIC SARCOMA.
Topics: Adenocarcinoma; Angiography; Animals; Blood Vessels; Fluorouracil; Mammary Neoplasms, Animal; Mammar | 1965 |
IN VITRO TEST SYSTEMS FOR CANCER CHEMOTHERAPY. 3. PRELIMINARY STUDIES OF SPONTANEOUS MAMMARY TUMORS IN MICE.
Topics: Alkylating Agents; Animals; Carcinoma, Ehrlich Tumor; Dactinomycin; Fluorouracil; Hydrocortisone; In | 1965 |
Human soluble tumor-associated antigens promote the suppression of rat mammary tumors by 5-fluorouracil and stimulate the functional activity of immune organs: Experimental and morphological studies.
Topics: Animals; Antigens, Neoplasm; Female; Fluorouracil; Lymph Nodes; Mammary Neoplasms, Animal; Rats; Rat | 2003 |
Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats.
Topics: Animals; Antigens, Bacterial; Antimetabolites, Antineoplastic; Bifidobacterium; Cytosine Deaminase; | 2006 |
Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 1996 |
Radiation enhancement by biochemical modulation and 5-fluorouracil.
Topics: 6-Aminonicotinamide; Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cell Di | 1997 |
Adjuvant post-operative chemotherapy in bitches with mammary cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinosarcoma; Chemotherapy, Ad | 2001 |
Chemotherapeutic activity of L-histidinol against spontaneous, autochthonous murine breast tumors.
Topics: Animals; DNA, Neoplasm; Female; Fluorouracil; Histidinol; Mammary Neoplasms, Animal; Mice; RNA, Neop | 1990 |